Abstract -Monoclonal antibodies (Mabs) and their immunoreactive fragments continue to be attractive, but as yet unproven, vehicles for the selective delivery of therapeutic quantities of 1oB to tumors for the purpose of boron neutron capture therapy ( B N O . Available chemical methodologies and boron-containing reagents for immunoprotein conjugation will be delineated along with the use of designed, precisely synthesized macromolecules which serve as "1OB-trailer" reagents for protein conjugation. The latter designed species have been investigated and are either synthetic peptide-like oligomers containing large quantities of boron in their component a-amino acids or they are hydrophilic polyamides comprised of boron-rich repeating units. Both classes of reagent are produced throu h solid-supported syntheses (Memfield methodology). Use of these precisely synthesizedq0B-trailer species as conjugation reagents equipped with analytically useful fluorescent labels may provide the 103 B-atoms per Mab molecule required for effective BNCT. This methodology provides Mab conjugation with a minimal loss of structural information while providing chemical reproducibility. The in vivo evaluation of this approach has led to the identification of potential improvements in the use of immunoproteins as vehicles for the selective delivery of boron (or other agents) to tumor cells. Consequently, the synthesis of a hydrophilic and boron-rich peptide which is structurally discrete and immunodirected is in progress.
INTRODUCTION
Of the many unusual properties of boron cluster compounds which might make them uniquely suited for specific applications in bioinorganic chemisay, biochemistry or medicine, the proposed use of derivatized polyhedral bordne ari!m\ or carboranes as carriers of 1oB for neutron capture is the most widely known (ref. 1,2). This hig' 1 . r localized cytotoxic binary nuclear reaction was first proposed by Locher in 1936 (ref. 3) as a possible means of cancer therapy and has since been known by the acronym, BNClr (Boron Neuuon Capture Therapy). The basis of (thermal) 0.02 to 0.05 eV neutron by a 1oB nucleus which results. The required 1oB isotope is unique among the light elements since it has the high nuclear cross-section of 3850 Barns and is available in twenty incorporated in enriched compounds at the 95% level.
this proposal is the capture of a reactor-generated slow 
Mev Released as Kinetic Energy
The 2.28 MeV released as kinetic energy and distributed between the a-particle and the 7Li+ ion gives these particles an effective distance of travel in tissue of approximately one cell diameter. During their passage through the interior of a cell, these energetic ions cause ionization tracking and cellular damage with associated cytotoxicity.
In fact, the a-particle is recognized as the most lethal product of nuclear reactions with a biologic lethality of 2.5 (or greater) that of an identical energy dose provided by y-radiation. Obviously, the selective concentration of l0B atoms on or within cancer cells followed by exposure of these cells to thermal neutrons provided by an efficient nuclear reactor (1011 to 1013 1n/cm2 sec) should kill tumor cells in the presence of normal (unlableled) cells. the H(n,y)D and 1 i N ( n , p ) " k 0.61 Mev While the nuclear cross-sections of these two processes are exceedingly small when compared to the 3850 Barns cross-section of "%I, their ability to generate cytotoxic products provides a non-selective background radiation dose. In order to administer cytoselective BNCT at a level capable of providing a significant therapeutic advantage, a minimum concentration of 1oB must be present in the tumor under attack. Depending upon the neutron current available, the uniformity of log dismbution within the tumor mass and the position of the targeted LOB atoms with respect to individual tumor cells, this concentration of I% may vary from 5 to 30 pg loB/g tumor. If 1% nuclei are located within tumor cells as opposed to being attached to the tumor cell surface, the concentration of loB required for therapy is significantly less. Workers in the BNCT field have generally agreed that 30 ppm of 1oB in tumor would assure effective therapy with available thermal neumn sources. The analysis of animal tissues obtained from boron localization experiments has been made easier by the development of inductively coupled plasma-atomic emission specaoscopy (ref. 4) for this purpose. Using this method, very small samples can be accurately assayed with boron levels in tissue of 0.1 ppm.
The issue of selective delivery of l0B to tumor as opposed to normal tissue has been addressed in several ways which make use of the physiological differences between tumor and normal cells. These boron-containing delivery systems include, but are not limited to, specific molecules such as porphyrins (ref. 1,2,8,9) . Regardless of the boron delivery method employed, the ratio of 1% in tumor to that in blood is critical and tumor to blood concentration ratios less than unity would be undesirable in therapy due to destruction of endothelial cells in that portion of the vascular system subjected to neutron irradiation.
DELIVERY OF BORON T O T U M O R S WITH BORON-LABELED I M M U N O P R O T E I N S
Of the many methods of selective boron delivery to tumor presently under consideration, the use of boron-labeled tumor-targeted monoclonal antibodies (Mabs) and their immunoreactive fragments (Fig. 1) would carry a radioactive or fluorescent group for analytical purposes attached to a terminal-NH2 group of their chain and the remaining -O H terminus would be free for conjugation with the lysine E-NH2 groups Peptide and polyamide trailers and their derivatives which contained the closo-1,2-C2BgH11-cage group were found to be too hydrophobic to employ in conjugation reactions with antibodies. Consequently, the reaction shown in Fig. 6 was developed which allows the quantitative conversion of closo-l,2-C2B1&I11-cages to the more hydrophilic [nido-7,8-C2BgH1.1-1: anion. As the sodium salts, these anionic groups imparted good water solubility to all species in which they were contained. 
THE SYNTHESIS OF TRAILER PEPTIDES
Having developed the synthesis of the essential a-amino acid, closo-CB, and its r-BOC derivative, the dansylated dipeptide (nido-CB)2(dansyl) and the dansylated undecapeptide (nido-CB)lO Lys(dpsyl)2 were constructed using standard Memfield peptide synthesis conditions. These syntheses are outlined in Fig. 7 and 8, respectively. Both peptides were characterized by IlB and IH lTNMR, mass spectra (as their closo derivatives prior to reaction with pyrrolidine), dansyl fluorescence intensities and HPLC chromatographic properties. 
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CONJUGATION OF TRAILER PEPTIDES WITH ANTI-CEA ANTIBODY T84.66
The IgG Mab selected for conjugation with the sodium salts of (nido-CB)z(dansyl) and (nido-CB)&ys(dansy1)2 was targeted for the carcinoembryonic antigen associated with LS174T human colon tumor xenografts employed in the biodismbution studies described below. For simplicity this Mab may hereafter be referred to by the abbreviated designation T84.
-m T84 h&&. A mixture of the dansylated anionic (nido-CB)~ [hereafter (CB)d and N-hydroxysulfosuccinirmde was treated with N,N-diisopropylcarbodiimide in dimethylformamide for one hour. The resulting active ester was incubated with T84 at pH 9.0 for lh, with the molar ratio of (CB)2 active ester to antibody being 10.5:l. A control reaction of T84 plus unactivated (CB)2 was also prepared. Initial purifications were performed by Centricon-30 diafiltration. Final purifications of the T84-(CB)2 conjugate and the control sample were by Superose 12 gel permeation chromatography. The control sample showed a sharp protein peak corresponding to monomeric antibody with a small amount of high molecular weight (HMW) species preceding the main antibody peak. Very little fluorescence was associated with either protein species indicating that (CB)2 was not bound nonspecifically to the antibody. The T84-(CB)2 conjugate showed a similar protein elution profile; however, a significant fluorescent component was observed indicating covalent attachment of (CB)2 to the antibody. Surprisingly, the HMW species showed a disproportionate amount of the fluorescent label. This suggests that the HMW species is much more reactive towards the (CB)2 active ester; or that a small percentage of the monomeric antibody repeatedly reacts at a disproportionately rapid rate with the (CB)2 active ester, thereby generating a highly conjugated HMW antibody species (accelerated or cascade conjugation).
The monomeric T84-(CB)2 conjugate and the control sample were collected and used for fluorescence, electrophoretic, immunoreactivity, and tumor-targeting analyses. Based on the measured fluorescence intensity and protein concentration of the T84-(CB)2 conjugate, an average of 3.5 (nido-CB)2 peptides (63 B-atoms) were incorporated per antibody molecule. SDS polyacrylamide gel electrophoresis (SDS-PAGE) of the monomeric T84-(CB)2 conjugate and the control sample exhibited identical electrophoretic migrations, indicating that there was no gross alteration of protein structure upon conjugation. Enzyme immunoassay of the monomeric TM-(CB)2 conjugate and an unmated sample of T84 Mab showed that they had identical immunoreactivities.
For tumor-targeting analyses, aliquots of monomeric T84-(CB)z and untreated T84 were radioiodinated using Na125I and chloramine-T. In the case of the T84-(CB)2 conjugate, this procedure is expected to label not only the protein, but also the (nido-CBh peptide due to the similar reactivity of the nido-Bg-moiety and tyrosine residues towards iodination (Fig. 5) . Because the stated goal of this research is the delivery of large amounts of boroncontaining compounds to tumor, nude mice bearing CEA-producing LS 174T tumor xenografts were administered % pg of unlabeled T84-(CB)2 together with 0.4 pg of 1251-T84-(CB)2 as a marker. Similar amounts of native and iodinated native T84 were used as a control. The biodismbution studies are summarized in the accompanying table.
. .
At the three time points studied (24, 48, and 120 hours) tumor was the principal site of uptake. The tumor-to-blood (T/B) ratio increased from 1.9 at 48 hours to 22.6 at 120 hours while the tumor-to-liver (TL) ratio remained nearly constant at 4.1 to 4.9. The control antibody, which was studied only at 120 hours, showed a T/L ratio of 11.6, although the T/B ratio was 9.3, somewhat less than for the T84-(CB)2 conjugate. The total tumor accumulation was 14.2, 14.5, and 7.0 %ID at the three time points for the T84-(CB)2 conjugate and 10.0 %ID for the control T84 Mab. of (nido-CB]lnLvs(dansv11., to T84 M&. Preliminary studies with didansylated anionic (nido-CB)l&ys [hereafter (CB)lo] suggested that the hydrophobic nature of the peptide led to its nonspecific binding to antibody, as well as incomplete recovery of the peptide and Mab-peptide conjugates during chromatographic procedures. A number of gel permeation chromatographic media and buffer formulations, including the use of organic solvents and nonionic detergents, were tested in order to alleviate these problems. Optimal results were obtained with Superose 12 in the presence of 0.05% Tween-20. The conjugation of (CB)lo to T84 was carried out essentially as described above for (CB)2, but at pH 8.5 with a molar ratio of peptide to antibody of 1O:l. Control reactions of T84 alone and T84 plus unactivated (CB)10 were also prepared. The conjugate and the two controls were brought to a final concentration of 0.05% Tween-20 and purified by Superose 12 chromatography. A sharp, monomeric antibody peak was obtained for untreated T84 with a minor component of HMW species. Only a trace amount of fluorescence was associated with these peaks. T84 treated with unactivated (CB)IO also showed a sharp, monomeric antibody peak. The HMW species was only slightly larger than that seen with T84 Mab alone. A small amount of fluorescence was associated with each of these peaks, with the free peptide eluting as a symmetrical peak after the monomeric antibody peak. For the T84-(CB),o conjugate, a sharp, monomeric antibody peak was obtained with a sizeable peak due to a HMW species. A UV-absorbing peak was later observed for N-hydroxysulfosuccinimide (-37 minutes). A significant amount of fluorescence was associated with the T84-(CB)lo conjugate relative to the unactivated (CB)lo peptide control. As was seen with the (CB)2 and other (CB)IO experiments, the fluorescence was disproportionately associated with the HMW species. The HMW and monomeric antibody species were collected and analyzed separately.
Background fluorescence due to the presence of 0.05% Tween-20 prevented quantitative fluorescence measurements. Recent studies have investigated the use of quantitative amino acid analysis for determining trailer substitution levels in Mab conjugates. Control hydrolyses of t-BOC-(CB)z, and -(CB),o revealed a ninhydrinreactive species eluting before aspartic acid, and therefore consistent with the presence of an anionic amino acid. The same amino acid was present in a hydrolysate of HMW T84-(CB)10conjugate. Quantitation of the amino acid revealed that the HMW conjugate contained an average of 6.3 (CB)lO peptides (570 boron atoms) per antibody. Immunoreactivities for the HMW and monomeric conjugates were compared to untreated T84 Mab. The monomeric conjugate retained its native immunoreactivity while there was a slight decrease in the immunoreactivity of the HMW coniugate. For tumor-targeting analyses, aliquots of both the HMW and monomeric T84-(CB)lo conjugates and untieated T84 Mab w&e radioiodinated as described above for the T84-(CB)2 conjugate. Nude mice bear- tumor showed an appreciable uptake of both the HMW and monomeric T84-(CB)lo conjugates, liver and spleen were again the organs of greatest avidity. In comparing the HMW and monomeric conjugates, slightly better tumor retention and decreased liver and spleen uptake were seen with the monomeric T84-(CB)lo conjugates. This suggests that the conjugation of (CB)10 peptide alone accelerates the deposition of T84 in liver and spleen, and that aggregate formation can further accelerate the deposition. The T84 Mab control behaved as expected and gave a bicdistribution similar to that observed in other experiments.
CONCLUSIONS DERIVED FROM TRAILER CONJUGATION AND BlODlSTRlBUTlON STUDIES
In progressing sequentially through the trailer reagent series (CBh to (CB)lo, the number of boron atoms attached to T84 Mab increased from an average of about 60 to 600.
Progression from (CB)2 to (CB)lO introduced the problem of nonspecific binding of Mab with peptide reagent, the formation of increased quantities of HMW species aided by a cascade conjugation reaction sequence and the enhancement of liver uptake of the conjugated Mabs relative to tumor. The nonspecific bonding of both activated and unactivated (CB)lo with Mab T84 must arise from the interaction of hydrophobic regions of Mab with ambiphilic (CB)IO. Conjugation of (CB)2 and (CB)lo trailers with Mab led to a disproportionate amount of fluorescent label in the HMW species or aggregate accompanied by the formation of additional aggregate. Mechanistically, the initial lysine conjugation reaction appears to open the Mab structure exposing additional reactive sites which are attacked ever more rapidly as conjugation and the resulting structural perturbation proceeds. The result is a cascade reactionsequence. As the native Mab structure becomes more disarrayed by this process, the number of interchain interactions between Mab molecules will correspondingly increase and the aggregate concentration will increase at the expense of monomeric Mab and its conjugates (Fig. 9) . Both the HMW and monomeric T84 Mab conjugates derived from (CB)lo have good enzyme immunoassay responses and the reduction in tumor uptake is the apparent result of the very effective competitive loss of Mab and HMW conjugates to liver. Tumor/blood ratios were favorably high in all cases.
These collected observations combined with the data of others (ref. 12-14) provide strong support to the conclusion that of full-sized Mab molecules with large, boron-rich conjugation reagents will become ever more complicated as the boron burden is increased. Therefore, if the splendid versatility of immunochemistry is to be applied to BNCT, radically different approaches will be required. Two such avenues of current research are briefly outlined below.
NEW APPROACHES TO THE IMMUNOCHEMICAL DELIVERY OF BORON
The results presented above suggest that the effective delivery of therapeutic quantities of 1oB to tumor might be achieved by (1) use of a greatly simplified chemically monofunctional FabSH antibody fragment related to T84.66 Mab and available by genetic engineering or (2) by synthesizing a bispecific (Fabl) (Fab2) antibody of the (Fab)2 class (see Fig. 1 ) which specifically binds tumor cell wall antigen (such as CEA) with one combining site, (Fabl), and with the other combining site, (Fab?), it binds a discrete, synthesizeb.-array of boron-rich oligomers based upon a 20-residue hydrophilic peptide or polyamide (20 mer species). In addition to these modifications of our attack upon the problem, the synthesis of very hydrophilic boron-rich a-amino acids equipped with polyhydroxy side chains (Fig. 10) is underway (ref. 15,16 ). -.
The ability of molecular engineering to provide monoclonal sources for species such as the simple antibody fragment FabSH shown in Fig. 11 suggests the adoption of strongly antigen-binding antibody fragments of this type which are monovalent with respect to cell wall antigen (CEA) complexation and monofunctional in the chemical sense (-SH group) . Figure 12 illustrates how a simple FabSH species may be linked to a single large collection of boron-rich HOCO[Mer]fl(dansyl) peptide chains bonded, in turn, to a small manifold peptide, HOCOMF(NH2)6, rich in lysine residues. The numerals shown in this figure depict the sequence of coupling reactions required to achieve the lo00 or so 10B-atoms attached to the immunoreactive Fab. The completed molecule to be used in targeting tumor cells is shown in Fig. 13 In practice the bispecific antibody would be iniected. alone, into the tumor-beariig animal and then binds to tumor antigen with the Fab'CEA portion of its structure.
After maximum tumor-loading has been achieved, the animal would then be innoculated with the haptenbearing boron carrier having approximately 103 available 1oB-atoms. Binding of this large molecule to the free and uncomplexed provide each involved cellular antigenic site with 103 10B-atoms without the use of conventional chemical bonds. The synthesis of the necessary bispecific antibody, (FabaA)(FabNi&), is outlined in Fig. 15 . The critical step in this sequence is the creation of a new hybridoma which produces the precursor IgG Nido-Mab which is targeted for the [nido-7,8 
